<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;A10B&quot;,&quot;href&quot;:&quot;atc/A10B.md&quot;},{&quot;label&quot;:&quot;empagliflozin&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;pd_Baron_2016_FPG&quot;,&quot;label&quot;:&quot;Baron_2016 \u00b7 FPG&quot;,&quot;group&quot;:&quot;PD&quot;,&quot;href&quot;:&quot;drugs/drug_empagliflozin/pd_Baron_2016_FPG.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;pd_Rascher_2025_HbA1c&quot;,&quot;label&quot;:&quot;Rascher_2025 \u00b7 HbA1c&quot;,&quot;group&quot;:&quot;PD&quot;,&quot;href&quot;:&quot;drugs/drug_empagliflozin/pd_Rascher_2025_HbA1c.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false},{&quot;id&quot;:&quot;pd_Sato_2024_HbA1c&quot;,&quot;label&quot;:&quot;Sato_2024 \u00b7 HbA1c&quot;,&quot;group&quot;:&quot;PD&quot;,&quot;href&quot;:&quot;drugs/drug_empagliflozin/pd_Sato_2024_HbA1c.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false}]"></div>

# empagliflozin

- **generic name:** empagliflozin
- **ATC codes:** `A10BD19`, `A10BD20`, `A10BD27`, `A10BK03`
- **DrugBank:** [DB09038](https://go.drugbank.com/drugs/DB09038) · **PubChem:** [CID 11949646](https://pubchem.ncbi.nlm.nih.gov/compound/11949646)
- **molar mass:** 450.91 g/mol (C23H27ClO7) — DrugBank
- **groups:** approved, investigational

## About

Empagliflozin is an anti-diabetic medicine (an SGLT2 inhibitor) used to lower blood sugar in type 2 diabetes, and also used for heart failure and chronic kidney disease. It is authorised in the European Union and widely used.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q5373824](https://www.wikidata.org/wiki/Q5373824) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| empagliflozin | parent | 450.91 | C23H27ClO7 | DrugBank | [11949646](https://pubchem.ncbi.nlm.nih.gov/compound/11949646) | Baron_2016, Rascher_2025 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-04 23:59 | 17:14 | 1/0/1 | 2/0/3 | 0/0/3 | 377,918/42,127 | ollama / qwen3.8:27b-mtp-q8_0 | 17 | 5/12 | 14/3 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.8). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: extracted</sub><br><sub>route_to: `engineer_replication`</sub> | [Baron_2016_reference](drugs/drug_empagliflozin/Empagliflozin_Baron2016_reference.md) | held back | 1-compartment, oral | 5 | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">built, not shipped</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.7). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: model_quarantined: Vd, Tlag left at base-class defaults</sub><br><sub>route_to: `scholar`</sub> | [Rascher_2025_reference](drugs/drug_empagliflozin/Empagliflozin_Rascher2025_reference.md) | held back | 1-compartment, oral | 6 | Rascher J et al., Pharmacokinetics and pharmacodynamics o…, British journal of clinical… (2025) | [10.1002/bcp.70096](https://doi.org/10.1002/bcp.70096) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Baron_2016_HbA1c](drugs/drug_empagliflozin/pd_Baron_2016_HbA1c.md) | Glycated hemoglobin ← empagliflozin · indirect response — drug inhibits the loss of Glycated hemoglobin | — | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="Animal study (mouse), not measured in people (from the LLM relevance screen, p(non-human) 1.00).">mouse</span> | [Sauer_2025_INa](drugs/drug_empagliflozin/pd_Sauer_2025_INa.md) | peak sodium current ← empagliflozin · direct Emax (saturable) effect | — | Sauer J et al., The sodium/glucose cotransporter 2 inhi…, American journal of physiol… (2025) | [10.1152/ajpheart.00363.2025](https://doi.org/10.1152/ajpheart.00363.2025) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Baron_2016_FPG](drugs/drug_empagliflozin/pd_Baron_2016_FPG.md) | Fasting plasma glucose ← empagliflozin · indirect response — drug inhibits the loss of Fasting plasma glucose | ▶ model + simulator | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Baron_2016_Genital_infection](drugs/drug_empagliflozin/pd_Baron_2016_Genital_infection.md) | Genital infection ← empagliflozin · categorical (graded) response model | — | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Baron_2016_Hypoglycemia](drugs/drug_empagliflozin/pd_Baron_2016_Hypoglycemia.md) | Confirmed hypoglycemic adverse events ← empagliflozin · categorical (graded) response model | — | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Baron_2016_UTI](drugs/drug_empagliflozin/pd_Baron_2016_UTI.md) | Urinary tract infection ← empagliflozin · categorical (graded) response model | — | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Baron_2016_Volume_depletion](drugs/drug_empagliflozin/pd_Baron_2016_Volume_depletion.md) | Volume depletion ← empagliflozin · categorical (graded) response model | — | Baron KT et al., Population Pharmacokinetics and Exposur…, Diabetes therapy : research… (2016) | [10.1007/s13300-016-0174-y](https://doi.org/10.1007/s13300-016-0174-y) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.222). The first reading is what the record holds.">cross-check: disputed</span> | [Rascher_2025_HbA1c](drugs/drug_empagliflozin/pd_Rascher_2025_HbA1c.md) | glycosylated haemoglobin ← empagliflozin · indirect response — drug inhibits the production of glycosylated haemoglobin | ▶ model + simulator | Rascher J et al., Pharmacokinetics and pharmacodynamics o…, British journal of clinical… (2025) | [10.1002/bcp.70096](https://doi.org/10.1002/bcp.70096) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> | [Sato_2024_HbA1c](drugs/drug_empagliflozin/pd_Sato_2024_HbA1c.md) | HbA1c change ← empagliflozin · direct sigmoid Emax (Hill) effect | ▶ model + simulator | Sato H et al., Model-based meta-analysis of HbA1c redu…, Scientific reports (2024) | [10.1038/s41598-024-76256-6](https://doi.org/10.1038/s41598-024-76256-6) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [van_2023_Body_weight](drugs/drug_empagliflozin/pd_van_2023_Body_weight.md) | Body weight ← empagliflozin · direct linear effect | model (no simulator) | van der Hoek S et al., Exposure-Response Analysis of the Sodiu…, Journal of personalized med… (2023) | [10.3390/jpm13050747](https://doi.org/10.3390/jpm13050747) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [van_2023_FPG](drugs/drug_empagliflozin/pd_van_2023_FPG.md) | Fasting plasma glucose ← empagliflozin · direct linear effect | model (no simulator) | van der Hoek S et al., Exposure-Response Analysis of the Sodiu…, Journal of personalized med… (2023) | [10.3390/jpm13050747](https://doi.org/10.3390/jpm13050747) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [van_2023_SBP](drugs/drug_empagliflozin/pd_van_2023_SBP.md) | Systolic blood pressure ← empagliflozin · direct linear effect | model (no simulator) | van der Hoek S et al., Exposure-Response Analysis of the Sodiu…, Journal of personalized med… (2023) | [10.3390/jpm13050747](https://doi.org/10.3390/jpm13050747) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [van_2023_UGE](drugs/drug_empagliflozin/pd_van_2023_UGE.md) | Urinary glucose excretion ← empagliflozin · direct linear effect | model (no simulator) | van der Hoek S et al., Exposure-Response Analysis of the Sodiu…, Journal of personalized med… (2023) | [10.3390/jpm13050747](https://doi.org/10.3390/jpm13050747) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.25). The first reading is what the record holds.">cross-check: disputed</span> | [van_2023_mGFR](drugs/drug_empagliflozin/pd_van_2023_mGFR.md) | Measured glomerular filtration rate ← empagliflozin · direct linear effect | model (no simulator) | van der Hoek S et al., Exposure-Response Analysis of the Sodiu…, Journal of personalized med… (2023) | [10.3390/jpm13050747](https://doi.org/10.3390/jpm13050747) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **ATP2A2** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Ain_2025](drugs/drug_empagliflozin/pgx_Ain_2025_ATP2A2_Q100.md) | Ain QT et al., Personalized Response to Empagliflozin…, Biomedicines (2025) | [10.3390/biomedicines13092095](https://doi.org/10.3390/biomedicines13092095) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **BDNF** | `Q100` — no parameter target — an association/risk finding, not a parameter shift | target | [Ain_2025](drugs/drug_empagliflozin/pgx_Ain_2025_BDNF_Q100.md) | Ain QT et al., Personalized Response to Empagliflozin…, Biomedicines (2025) | [10.3390/biomedicines13092095](https://doi.org/10.3390/biomedicines13092095) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.25). The first reading is what the record holds.">cross-check: partial</span> | **UGT1A9** | `Q27` · CL/F | metabolism | [Golovina_2023](drugs/drug_empagliflozin/pgx_Golovina_2023_UGT1A9_Q27.md) | Golovina EL et al., [Clinical effectiveness and pharmacokin…, Terapevticheskii arkhiv (2023) | [10.26442/00403660.2023.08.202326](https://doi.org/10.26442/00403660.2023.08.202326) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=empagliflozin) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| absorption | kidney | `ABCB1` substrate | DrugBank actor |
| absorption | liver | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| absorption | mammary gland | `ABCG2` substrate | DrugBank actor |
| absorption | placenta | `ABCB1` substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| absorption | testis | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| metabolism | kidney | `UGT1A9` metabolism/substrate, `UGT2B7` substrate | DrugBank actor |
| metabolism | liver | `SLCO1B1` substrate, `SLCO1B3` substrate, `UGT1A3` substrate, `UGT1A9` metabolism/substrate, `UGT2B7` substrate | DrugBank actor |
| metabolism | small intestine | `UGT2B7` substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | `SLC22A8` substrate | DrugBank actor |
| — | kidney | `SLC5A2` inhibitor | DrugBank actor |

<sub>Actors without a tissue in the table: ATP2A2 (target), BDNF (target), UGT1A8 (substrate).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 68 matched, 44 returned
- **screened:** 10  ·  **relevant:** 2
- **records:** 2  ·  extracted 1  ·  needs_review 1  ·  rejected 0  ·  stale 1
- **scholar-agent fallback query used:** not captured

## Full text wanted

_7 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Jiang_2024.pdf` | Jiang X et al., A Population Pharmacokinetic Study to C…, Pharmaceuticals (Basel, Swi… (2024) | popPK | 10 | [10.3390/ph17040522](https://doi.org/10.3390/ph17040522) | [38675482](https://pubmed.ncbi.nlm.nih.gov/38675482) | The paper describes a population PK study for empagliflozin with a two-compartment model, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence text. |
| `Mondick_2016.pdf` | Mondick J et al., Mixed-effects modelling to quantify the…, Diabetes, obesity & metabol… (2016) | popPK | 9 | [10.1111/dom.12597](https://doi.org/10.1111/dom.12597) | [26511213](https://pubmed.ncbi.nlm.nih.gov/26511213) | The paper describes a population PK model for empagliflozin, but the specific numeric PK parameter values (CL, V, etc.) are not present in the provided evidence, which only lists PD outcomes (RTg). |
| `Mondick_2018.pdf` | Mondick J et al., Population Pharmacokinetic- Pharmacodyn…, Journal of clinical pharmac… (2018) | popPK | 8 | [10.1002/jcph.1051](https://doi.org/10.1002/jcph.1051) | [29251772](https://pubmed.ncbi.nlm.nih.gov/29251772) | The paper describes a population PK-PD model for empagliflozin in humans, but the specific numeric PK parameter values (CL, V, etc.) are not listed in the provided abstract, only PD outcomes (RTG). |
| `Riggs_2014.pdf` | Riggs MM et al., Exposure-response modelling for empagli…, British journal of clinical… (2014) | pd | 5 | [10.1111/bcp.12453](https://doi.org/10.1111/bcp.12453) | [24964723](https://www.ncbi.nlm.nih.gov/pubmed/24964723) | metadata signals extractable PD data (Exposure-response) |
| `Yao_2023.pdf` | Yao X et al., A model-based meta analysis study of so…, CPT: pharmacometrics & syst… (2023) | pd | 5 | [10.1002/psp4.12934](https://doi.org/10.1002/psp4.12934) | [36890732](https://www.ncbi.nlm.nih.gov/pubmed/36890732) | metadata signals extractable PD data (PK/PD) |
| `Xu_2023.pdf` | Xu B et al., Role of SLC5A2 polymorphisms and effect…, Molecular biology reports (2023) | pgx | 8 | [10.1007/s11033-023-08836-0](https://doi.org/10.1007/s11033-023-08836-0) | [37819499](https://www.ncbi.nlm.nih.gov/pubmed/37819499) | metadata signals extractable PGX data (SLC5A2, PK/PD-context) |
| `Du_2025.pdf` | Du W et al., In vivo assessment of pharmacokinetic i…, PeerJ (2025) | pgx | 7 | [10.7717/peerj.19662](https://doi.org/10.7717/peerj.19662) | [40656939](https://www.ncbi.nlm.nih.gov/pubmed/40656939) | metadata signals extractable PGX data (Ugt2b7, PK/PD-context) |

<sub>queue written 2026-10-04T23:44:11.639503+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Agarwal_2026 | irrelevant | 0 | 0 | The paper is a clinical trial analysis focusing on blood pressure and albuminuria outcomes, containing no pharmacokinetic parameters for empagliflozin. |
| PGx | Alami_2025 | not_relevant | 0 | 0 | The study investigates neuroprotective mechanisms and brain distribution in cellular/animal models without reporting any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| popPK | Banerjee_2023 | irrelevant | 0 | 0 | The paper is a meta-analysis of clinical outcomes (gout risk) and does not report pharmacokinetic parameters for empagliflozin. |
| PGx | Bloomgarden_2018 | not_relevant | 0 | 0 | The paper discusses the association between branched-chain amino acids and diabetes, and mentions empagliflozin only in the context of its effects on metabolomics, without reporting any pharmacogenomic effects on PK or PD parameters. |
| PGx | Chen_2026 | not_relevant | 0 | 0 | The paper investigates the SGLT2-independent metabolic mechanisms of empagliflozin in heart failure models, not the effect of genetic variants on the drug's pharmacokinetics or pharmacodynamics. |
| popPK | Dogan_2023 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of oxidative stress and cell viability in H9c2 cardiomyocytes, reporting no pharmacokinetic parameters (CL, V, ka, etc.) for empagliflozin. |
| PGx | Du_2025 | not_relevant | 0 | 0 | The study investigates drug-drug interactions (empagliflozin with sorafenib) in rats, not pharmacogenomic effects of gene variants on empagliflozin PK/PD. |
| popPK | Gashaw_2026 | irrelevant | 0 | 0 | The study evaluates the pharmacodynamics of vicadrostat (corticosteroid levels) and empagliflozin is only a background comparator drug, with no PK parameters reported for empagliflozin. |
| PGx | Golovina_2023 | not_relevant | 5 | 2 | The paper is a review discussing the general pharmacokinetics of gliflozins and the role of UGT1A9, but it does not report specific quantitative pharmacogenomic effect sizes for empagliflozin. |
| PGx | Grünert_2024 | not_relevant | 0 | 0 | The paper is a consensus guideline for treating GSD Ib with empagliflozin and does not report pharmacogenomic effects on PK/PD parameters. |
| PGx | Halligan_2022 | not_relevant | 0 | 0 | The paper reports clinical outcomes in patients with a specific disease (GSD Ib) but does not analyze how genetic variants affect the pharmacokinetics or pharmacodynamics of empagliflozin. |
| popPK | Hassan_2025 | irrelevant | 0 | 0 | The study analyzes the effect of empagliflozin on the biomarker CA125 and does not report any pharmacokinetic parameters (CL, V, ka, etc.) for empagliflozin. |
| PGx | Herat_2020 | not_relevant | 0 | 0 | The paper investigates the metabolic effects of SGLT2 inhibitors in diabetic mouse models but does not report any pharmacogenomic analysis or genotype-dependent changes in PK/PD parameters. |
| popPK | Jiang_2024 | relevant | 10 | 0 | The paper describes a population PK study for empagliflozin with a two-compartment model, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence text. |
| PGx | Kaur_2021 | not_relevant | 2 | 1 | The text is an abstract of a review article that discusses pharmacogenomics in general terms but does not report specific quantitative data or fitted effect sizes for empagliflozin. |
| PGx | Lu_2020 | not_relevant | 0 | 0 | The paper investigates the molecular mechanism of empagliflozin's effect on uric acid transporters in mice and cells, but does not report any pharmacogenomic effects (gene variants) on the drug's PK or PD parameters. |
| PGx | Mitra_2026 | not_relevant | 0 | 0 | The paper describes the transporter-mediated disposition of a vicadrostat metabolite, not the pharmacogenomics of empagliflozin. |
| popPK | Mondick_2016 | relevant | 9 | 2 | The paper describes a population PK model for empagliflozin, but the specific numeric PK parameter values (CL, V, etc.) are not present in the provided evidence, which only lists PD outcomes (RTg). |
| popPK | Mondick_2018 | relevant | 8 | 2 | The paper describes a population PK-PD model for empagliflozin in humans, but the specific numeric PK parameter values (CL, V, etc.) are not listed in the provided abstract, only PD outcomes (RTG). |
| popPK | Mouawad_2026 | irrelevant | 0 | 0 | The paper is a review of methotrexate nephrotoxicity where empagliflozin is only mentioned as a repurposed agent in animal studies without providing any PK parameters for it. |
| PGx | Mouawad_2026 | not_relevant | 0 | 0 | The paper discusses methotrexate pharmacogenomics and mentions empagliflozin only as a potential nephroprotective agent in animal studies, without reporting any pharmacogenomic effects on empagliflozin's PK or PD. |
| PGx | Nowak-Szwed_2025 | not_relevant | 0 | 0 | The paper investigates epigenetic biomarkers (sirtuins/miRNAs) for predicting clinical response (LVEF) to empagliflozin, not pharmacogenomic effects on PK/PD parameters. |
| PGx | Okada_2020 | not_relevant | 0 | 0 | The paper investigates the off-target anticancer effects of dapagliflozin and does not report pharmacogenomic effects on the PK or PD parameters of empagliflozin. |
| PGx | Rathmann_2021 | not_relevant | 0 | 0 | The paper is a review that explicitly states no relationship was found between SLC5A2 variants and response to empagliflozin. |
| popPK | Riggs_2014 | irrelevant | 0 | 0 | no_text gate: only 131 chars of text extracted (&lt; 400) |
| popPK | Sato_2024 | irrelevant | 0 | 0 | The study is a model-based meta-analysis of pharmacodynamic (HbA1c reduction) data, not a pharmacokinetic study reporting disposition parameters like clearance or volume for empagliflozin. |
| popPK | Sauer_2025 | irrelevant | 0 | 0 | The study investigates the electrophysiological mechanism of empagliflozin as a pharmacological chaperone in cardiomyocytes, not its pharmacokinetic disposition parameters. |
| PGx | Shao_2024 | not_relevant | 0 | 0 | The study reports clinical outcomes (neutrophil count, safety) of empagliflozin in patients with a specific genetic disease (GSD Ib), but does not report how a gene variant affects the pharmacokinetics or pharmacodynamics of the drug itself. |
| popPK | Wang_2024 | relevant | 8 | 0 | The paper describes a population PK model for empagliflozin, but the specific numeric parameter estimates (CL, V, etc.) are not present in the provided text, only diagnostic plots and study characteristics. |
| PGx | Xu_2023 | not_relevant | 4 | 2 | The text is a review summarizing general associations for SGLT2 inhibitors and notes that SLC5A2 variants show no significant effect on empagliflozin response, without reporting specific quantitative PK/PD effect sizes for empagliflozin. |
| popPK | Yao_2023 | irrelevant | 0 | 0 | no_text gate: only 79 chars of text extracted (&lt; 400) |
| PD | Yao_2023 | not_relevant | 0 | 0 | The provided text is only the title of a meta-analysis and does not contain the full text, data, or specific numeric PD parameters for empagliflozin. |
| popPK | van_2023 | irrelevant | 3 | 2 | The study is an exposure-response analysis using non-compartmental analysis (NCA) to estimate AUC, not a population pharmacokinetic study reporting compartmental parameters (CL, V, Q, ka) or a population PK model. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-04 23:44 UTC</sub>
